Comprehensive, easy-to-understand information about this condition
How we create this content →Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning hereditary angioedema with normal C1inh not related to F12 or PLG variant
Updated Feb 6, 2026
BioCryst is acquiring Astria Therapeutics in a cash-and-stock deal to enhance its portfolio with a long-acting preventive therapy for hereditary angioedema. This acquisition reflects a strategic shift in venture firms' preferences as the biotech sector recovers.
Intellia is set to report Phase 3 trial results for a potential treatment for hereditary angioedema in the first half of 2026, amidst a backdrop of significant clinical trial activity in rare diseases. Despite recent challenges, including a study participant's death and program suspensions, the biotech sector is regaining momentum with key readouts expected across various conditions.